Trial · NCT04305405
Results by group167
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 167
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clearance of Benralizumab | All Participants | 0.156 | Standard Deviation 0.0598 | liter (L) per day | |
| Area Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab | Benralizumab Dose 1, Aged 6-11 Years | 36918.01 | Geometric Coefficient of Variation 24.61 | nanogram*day per milliliter (ng*day/mL) | |
| Area Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab | Benralizumab Dose 2, Aged 6-11 Years | 75593.37 | Geometric Coefficient of Variation 39.96 | nanogram*day per milliliter (ng*day/mL) | |
| Area Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab | Benralizumab Dose 1, Aged 6-14 Years | 36918.01 | Geometric Coefficient of Variation 24.61 | nanogram*day per milliliter (ng*day/mL) | |
| Area Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab | Benralizumab Dose 2, Aged 6-14 Years | 73670.51 | Geometric Coefficient of Variation 38.86 | nanogram*day per milliliter (ng*day/mL) | |
| Maximum Observed Serum Concentration (Cmax) of Benralizumab | Benralizumab Dose 1, Aged 6-11 Years | 1901.18 | Geometric Coefficient of Variation 28.42 | ng/mL | |
| Maximum Observed Serum Concentration (Cmax) of Benralizumab | Benralizumab Dose 2, Aged 6-11 Years | 3118.69 | Geometric Coefficient of Variation 47.35 | ng/mL | |
| Maximum Observed Serum Concentration (Cmax) of Benralizumab | Benralizumab Dose 1, Aged 6-14 Years | 1901.18 | Geometric Coefficient of Variation 28.42 | ng/mL | |
| Maximum Observed Serum Concentration (Cmax) of Benralizumab | Benralizumab Dose 2, Aged 6-14 Years | 3090.85 | Geometric Coefficient of Variation 43.66 | ng/mL | |
| Terminal Phase Elimination Half-Life (t1/2) of Benralizumab | All Participants | 14.4 | Full Range 6.94 to 23.4 | day | |
| Time to Achieve Maximum Observed Serum Concentration (Tmax) of Benralizumab | Benralizumab Dose 1, Aged 6-11 Years | 6.91 | Full Range 0.93 to 14.95 | day | |
| Time to Achieve Maximum Observed Serum Concentration (Tmax) of Benralizumab | Benralizumab Dose 2, Aged 6-11 Years | 7.26 | Full Range 1.10 to 14.01 | day | |
| Time to Achieve Maximum Observed Serum Concentration (Tmax) of Benralizumab | Benralizumab Dose 1, Aged 6-14 Years | 6.91 | Full Range 0.93 to 14.95 | day | |
| Time to Achieve Maximum Observed Serum Concentration (Tmax) of Benralizumab | Benralizumab Dose 2, Aged 6-14 Years | 7.94 | Full Range 1.10 to 14.01 | day | |
| Trough Concentration of Benralizumab at Week 16 (Ctrough16) | Benralizumab Dose 1, Aged 6-11 Years | 142.42 | Geometric Coefficient of Variation 256.34 | ng/mL | |
| Trough Concentration of Benralizumab at Week 16 (Ctrough16) | Benralizumab Dose 2, Aged 6-11 Years | 339.35 | Geometric Coefficient of Variation 409.24 | ng/mL | |
| Trough Concentration of Benralizumab at Week 16 (Ctrough16) | Benralizumab Dose 1, Aged 6-14 Years | 142.42 | Geometric Coefficient of Variation 256.34 | ng/mL | |
| Trough Concentration of Benralizumab at Week 16 (Ctrough16) | Benralizumab Dose 2, Aged 6-14 Years | 340.46 | Geometric Coefficient of Variation 363.69 | ng/mL | |
| Change From Baseline in Peripheral Blood Eosinophil Count up to Week 48 | Benralizumab Dose 1, Aged 6-11 Years | Week 4 | -447.3 | Standard Deviation 283.76 | cells/microliters |
| Change From Baseline in Peripheral Blood Eosinophil Count up to Week 48 | Benralizumab Dose 2, Aged 6-11 Years | Week 4 | -436.9 | Standard Deviation 408.28 | cells/microliters |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04305405/results